홍유석 지놈앤컴퍼니 대표 "올해 LO 바이오USA서 구체화" [현장+]

Genome & Company's focus on novel cancer targets like CNTN4 and ITGB4 reflects a broader biotech industry shift toward differentiation—moving away from saturated ADC targets like HER2 and Nectin-4 to capture first-in-class premiums. With big pharma facing patent cliffs and seeking innovative assets, companies that establish first-mover advantage in untapped targets can command significantly higher valuations and deal terms, even at preclinical stages. The success of these planned licensing partnerships will signal whether novel target strategy can compete with clinical-stage assets in the biotech partnering market.